Clesrovimab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Clesrovimab: clinical details
Prescribing considerations
- Use according to current official RSV recommendations.
- Clinical data are limited in extremely premature infants and unavailable in some very low postmenstrual-age or low-weight groups; assess individual benefit and uncertainty.
- Assess bleeding risk before intramuscular administration in thrombocytopenia or coagulation disorders.
- Record the product name and batch number for traceability.
- Confirm a negative rapid antigen result with RT-PCR when clinical findings remain consistent with RSV infection.
Contraindications and cautions
- Hypersensitivity to clesrovimab or any excipient.
Monitoring
- Be prepared to recognise and manage clinically significant hypersensitivity or anaphylaxis.
- Monitor for injection-site reactions, rash and urticaria.
- No specific routine laboratory monitoring is described; report suspected adverse reactions through the Yellow Card Scheme.
Clinical pharmacology
Clesrovimab is a fully human IgG1 kappa neutralising antibody with an Fc modification that extends serum persistence. It binds antigenic site IV of the RSV fusion protein, prevents viral entry into cells and is degraded through normal protein-catabolic pathways.
Formulation and product differences
- Ready-to-use solution in a pre-filled syringe, supplied with or without needles depending on the pack.
- Clear to slightly opalescent and colourless to slightly yellow.
- Contains polysorbate 80, which may cause allergic reactions.
- Refrigerate, protect from light, and do not freeze, shake or mix with another medicine.
Clesrovimab preparations and strengths
Injection
Route: Parenteral
Strengths: 105 mg
Clesrovimab interactions
Formal interaction studies have not been performed, but clinically important metabolic interactions are considered unlikely.
Routine childhood vaccines
May be given at the same visit using a separate syringe and injection site. They must not be mixed with clesrovimab.
Anticoagulants or other treatments affecting clotting
Intramuscular injection may increase bruising or bleeding, so the administering team should assess the infant’s bleeding risk.
Palivizumab
There are no data to guide substitution with clesrovimab after palivizumab prophylaxis has begun.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.